AstraZeneca wins shareholder backing for NYSE listing in US pivot
PositiveFinancial Markets

AstraZeneca has received strong support from its shareholders for its decision to list on the New York Stock Exchange, marking a significant pivot towards the US market. This move is important as it not only enhances the company's visibility and access to capital but also aligns with its growth strategy in a key market. The backing from shareholders reflects confidence in AstraZeneca's future prospects and its commitment to innovation in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System











